News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ferring Pharmaceuticals Release: UK National Institute for Clinical Excellence (NICE) Guidance Recommends FIRMAGON® (Degarelix) For The Treatment Of Advanced Hormone-Dependent Prostate Cancer Only In People With Spinal Metastases Who Present With Signs Or Symptoms Of Impending Spinal Cord Compression (ISCC)


4/15/2014 9:25:04 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WEST DRAYTON, England--(BUSINESS WIRE)--The National Institute for Health and Care Excellence (NICE) today issued its Final Appraisal Determination (FAD) recommending FIRMAGON® (degarelix) as an option for treating advanced hormone-dependent prostate cancer, only in adults with spinal metastases who present with signs or symptoms of spinal cord compression. Both Ferring and members of the healthcare community are disappointed that the recommended use is so restrictive.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES